Peripheral T-cell lymphoma (PTCL) is a rare, heterogeneous malignancy. Of the 619 patients with relapsed and refractory (R/R) aggressive lymphoma enrolled in the Canadian Cancer Trials Group LY.12 phase 3 trial, 59 (9.5%) had PTCL. Among these, 81% had advanced stage disease, 41% had an International Prognostic Score ≥3, and 41% were refractory to primary therapy. Within the PTCL cohort, the overall response rate after two cycles of salvage chemotherapy was 36%; no difference was observed between dexamethasone, cytarabine, cisplatin (10/30, 33%), and gemcitabine, cisplatin, dexamethasone (11/29, 38%) therapy. At one year, event-free survival (EFS) was 16% and overall survival (OS) was 28%. For PTCL patients, who received autologous stem cell transplant, two-year EFS and OS were 21% and 42%, respectively. Patients with PTCL had inferior OS (HR 0.49, p <.0001) and EFS (HR 0.53, p <.0001) compared to B-cell lymphoma. Outcomes for patients with R/R PTCL are poor with currently available therapies.

Salvage chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: a subset analysis of the Canadian Cancer Trials Group LY.12 randomized phase 3 study* / Skamene, Tanya; Crump, Michael; Savage, Kerry J.; Reiman, Tony; Kuruvilla, John; Good, David; Lebrun, David; Meyer, Ralph M.; Sehn, Laurie H.; Soulières, Denis; Stakiw, Julie; Laferriere, Nicole; Luminari, Stefano; Shepherd, Lois E.; Djurfeldt, Marina; Zhu, Liting; Chen, Bingshu E.; Hay, Annette E.. - In: LEUKEMIA & LYMPHOMA. - ISSN 1042-8194. - 58:10(2017), pp. 2319-2327. [10.1080/10428194.2017.1312379]

Salvage chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: a subset analysis of the Canadian Cancer Trials Group LY.12 randomized phase 3 study*

Luminari, Stefano
Investigation
;
2017

Abstract

Peripheral T-cell lymphoma (PTCL) is a rare, heterogeneous malignancy. Of the 619 patients with relapsed and refractory (R/R) aggressive lymphoma enrolled in the Canadian Cancer Trials Group LY.12 phase 3 trial, 59 (9.5%) had PTCL. Among these, 81% had advanced stage disease, 41% had an International Prognostic Score ≥3, and 41% were refractory to primary therapy. Within the PTCL cohort, the overall response rate after two cycles of salvage chemotherapy was 36%; no difference was observed between dexamethasone, cytarabine, cisplatin (10/30, 33%), and gemcitabine, cisplatin, dexamethasone (11/29, 38%) therapy. At one year, event-free survival (EFS) was 16% and overall survival (OS) was 28%. For PTCL patients, who received autologous stem cell transplant, two-year EFS and OS were 21% and 42%, respectively. Patients with PTCL had inferior OS (HR 0.49, p <.0001) and EFS (HR 0.53, p <.0001) compared to B-cell lymphoma. Outcomes for patients with R/R PTCL are poor with currently available therapies.
2017
15-mag-2017
58
10
2319
2327
Salvage chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: a subset analysis of the Canadian Cancer Trials Group LY.12 randomized phase 3 study* / Skamene, Tanya; Crump, Michael; Savage, Kerry J.; Reiman, Tony; Kuruvilla, John; Good, David; Lebrun, David; Meyer, Ralph M.; Sehn, Laurie H.; Soulières, Denis; Stakiw, Julie; Laferriere, Nicole; Luminari, Stefano; Shepherd, Lois E.; Djurfeldt, Marina; Zhu, Liting; Chen, Bingshu E.; Hay, Annette E.. - In: LEUKEMIA & LYMPHOMA. - ISSN 1042-8194. - 58:10(2017), pp. 2319-2327. [10.1080/10428194.2017.1312379]
Skamene, Tanya; Crump, Michael; Savage, Kerry J.; Reiman, Tony; Kuruvilla, John; Good, David; Lebrun, David; Meyer, Ralph M.; Sehn, Laurie H.; Soulières, Denis; Stakiw, Julie; Laferriere, Nicole; Luminari, Stefano; Shepherd, Lois E.; Djurfeldt, Marina; Zhu, Liting; Chen, Bingshu E.; Hay, Annette E.
File in questo prodotto:
File Dimensione Formato  
skamene2017.pdf

Accesso riservato

Tipologia: Versione pubblicata dall'editore
Dimensione 1.21 MB
Formato Adobe PDF
1.21 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1153061
Citazioni
  • ???jsp.display-item.citation.pmc??? 12
  • Scopus 20
  • ???jsp.display-item.citation.isi??? 19
social impact